NCT01164163已完成1 期
A Phase I Study of JAK Inhibition (INCB018424) in Children With Relapsed or Refractory Solid Tumors, Leukemias, and Myeloproliferative Neoplasms
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 49
- 试验地点
- 24
- 主要终点
- Pharmacokinetics
研究概览
简要总结
RATIONALE: INCB18424 (Ruxolitinib) may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
PURPOSE: This phase 1 clinical trial is studying the side effects and best dose of INCB18424 in treating young patients with relapsed or refractory solid tumor, leukemia, or myeloproliferative disease.
详细描述
OBJECTIVES:
Primary
- To estimate the maximum-tolerated dose and/or recommended phase II dose of oral JAK inhibitor INCB18424 administered continuously, twice daily to pediatric patients with relapsed or refractory solid tumors.
- To define and describe the toxicities of this treatment administered on this schedule in pediatric patients with relapsed or refractory solid tumors, leukemias, or myeloproliferative neoplasms (MPNs).
- To characterize the pharmacokinetics of this treatment in pediatric patients with relapsed or refractory solid tumors, leukemias, or MPNs.
Secondary
- To preliminarily define the antitumor activity of this treatment within the confines of a phase I study.
- To assess the biologic activity of oral JAK inhibitor INCB18424 upon JAK-STAT signaling in pediatric patients with relapsed or refractory solid tumors, leukemias, or MPNs.
- To assess the cytotoxicity and biologic activity of oral JAK inhibitor INCB18424 upon phosphosignaling and mutation burden in pediatric patients whose leukemias or MPNs have known CRLF2 and/or JAK mutations.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 1 Year 至 21 Years（Child, Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究组 & 干预措施
Treatment (Ruxolitinib)
Experimental
干预措施: ruxolitinib phosphate (Drug)
Treatment (Ruxolitinib)
Experimental
干预措施: laboratory biomarker analysis (Other)
Treatment (Ruxolitinib)
Experimental
干预措施: pharmacological study (Other)
结局指标
主要结局
Pharmacokinetics
时间窗: Up to 28 days
Toxicity
时间窗: 30 days post treatment
Maximum-tolerated dose and/or recommended phase II dose
时间窗: 28 days
次要结局
- Toxicity and biologic activity(Day 1 and Day 15)
- Antitumor activity(Up to 30 days post treatment)
研究者
研究点 (24)
Loading locations...
相似试验
已完成
1 期
Erlotinib, Paclitaxel, and Carboplatin Combined With Radiation Therapy for Stage III Non-Small Cell Lung CancerLung CancerNCT00278148Nathan Pennell, MD, PhD32
招募中
1 期
Ruxolitinib and Enzalutamide for the Treatment of Metastatic Castration-Resistant Prostate CancerCastration-Resistant Prostate CarcinomaMetastatic Prostate AdenocarcinomaStage IVB Prostate Cancer AJCC v8NCT06616155University of Michigan Rogel Cancer Center20
进行中（未招募）
不适用
A Randomized Study of the JAK Inhibitor INCB018424 Tablets Compared to Best Available Therapy in Subjects with Primary Myelofibrosis (PMF), Post-Polycythemia Vera-Myelofibrosis (PPV-MF) or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) - COMFORT IIMedDRA version: 12.0Level: LLTClassification code 10028537Term: MyelofibrosisMyelofibrosisEUCTR2009-009858-24-ITIncyte Corporation150
已完成
1 期
Open Label Ruxolitinib (INCB018424) in Patients With Myelofibrosis and Post Polycythemia Vera/Essential Thrombocythemia MyelofibrosisThrombocytosisMyelofibrosisPolycythemia VeraNCT00509899Incyte Corporation154
终止
2 期
Ruxolitinib in Patients With Breast CancerBreast CancerNCT01562873Dana-Farber Cancer Institute21